Nightingale Health

What Nightingale Health does

Nightingale Health is a Finnish health technology company founded in 2013 and headquartered in Helsinki. Its core offering is a proprietary NMR (Nuclear Magnetic Resonance) metabolomics platform that measures over 250 biomarkers from a single blood sample to predict risk for multiple chronic diseases — including cardiovascular disease, Type 2 diabetes, dementia, heart failure, and cancer. The platform has been validated across more than 900 scientific publications and is supported by regulatory certifications including CE marking for its at-home IVD blood collection kit, ISO 13485, ISO/IEC 27001, and a New York State clinical laboratory permit.

The company serves four primary customer segments: healthcare providers (hospitals, clinics, laboratories), insurers (underwriting and wellness programs), governments and health systems (population screening and preventive healthcare), and medical researchers/biobanks (large-scale metabolomic studies). It also operates a direct-to-consumer channel under the Nightingale Home, Nightingale Pro, My Nightingale, and Livit by Nightingale Health brands, including an at-home fingerstick blood collection device with results delivered via mobile application. Nightingale is publicly listed on Nasdaq First North Growth Market Finland following a 2021 IPO that raised approximately EUR 110 million from institutional investors.

Nightingale generates revenue through a mix of subscription-based and per-test pricing. Consumer pricing includes a Terveystalo + Nightingale Well-being Membership at approximately EUR 120 per year and unit-priced at-home tests distributed via Yliopiston Apteekki pharmacies. Enterprise and government contracts are quote-based and span laboratory services, population screening, and biobank research collaborations. Distribution is operated through own-laboratories in Finland, the US, the UK, Japan, and Singapore, complemented by strategic channel partners including Terveystalo, Yliopiston Apteekki, 23andMe, and Formula 100 Health. The business has scaled internationally through partnerships with BioBank Japan, UK Biobank, THL Biopankki, and 23andMe, and through acquisitions of Yolife GmbH (2021), Negen Oy (2022), and My Nightingale (2024).

Name

Nightingale Health

Legal name

Nightingale Health Oyj

Website

https://nightingalehealth.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Nightingale Health is a Finnish public health technology company that uses proprietary NMR metabolomics to measure 250 biomarkers from a single blood sample, providing multi-disease risk prediction for healthcare providers, insurers, governments, biobanks, and consumers across Europe, North America, and Asia.

Ownership category

akta.pro rank

Product category

Preventive Blood Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Metabolomics & Lipidomics Services (HLAGANAG)

akta.pro secondary industries

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Blood biomarker analysis
• Metabolomics diagnostics
• Disease risk prediction
• Preventive health screening
• Clinical blood testing

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare Services Revenue: Revenue from providing blood analysis services to healthcare providers, insurance companies, and governments. The company offers subscription-based and per-test pricing models for its Nightingale Health Check and disease risk assessment services.
2. Consumer Health Services: Direct-to-consumer revenue through wellness membership programs like the Terveystalo + Nightingale Well-being Membership at EUR 9.90/month, and Nightingale Home/Pro service models for individual health monitoring.
3. Research and Biobank Services: Revenue from research collaborations with biobanks (BioBank Japan, UK Biobank, THL Biopankki) for large-scale metabolomic analysis of population samples for medical research purposes.
4. Technology Licensing: Licensing of proprietary NMR metabolomics technology and disease risk prediction algorithms to healthcare partners, research institutions, and international markets.

Pricing tiers

Go-to-market motion3 records

Distribution channels7 records

Marketing channels8 records

Core offering

Nightingale Health provides an advanced blood analysis platform that uses proprietary NMR (Nuclear Magnetic Resonance) metabolomics technology to measure over 250 biomarkers from a single blood sample, enabling multi-disease risk prediction (cardiovascular disease, type 2 diabetes, dementia, cancer) for healthcare providers, insurers, governments, researchers, and consumers through laboratory-based and at-home service models.

Product overview

Nightingale Health offers a unified health check platform with multiple service models and research products. The core offering consists of Nightingale Health Check and Remote Health Check, which provide multi-disease risk detection from a single blood sample using proprietary NMR metabolomics technology. For consumers, Nightingale Home enables self-collected fingerstick blood samples, while Nightingale Pro serves healthcare providers requiring detailed venous blood analysis with comprehensive blood values. The company also provides research services including venous blood analysis, dried blood analysis (Nightingale Kit), urine analysis, metabolomics, and proteomics through its research portal. Partnerships include the Terveystalo Well-being Membership combining blood analysis with lifestyle coaching. The platform has been validated in over 900 scientific publications and serves B2B and B2G customers across laboratories in the US, UK, Japan, Singapore, and Finland.

Differentiator

Problem solved

Functional benefit

Brands

• Nightingale Home: Consumer self-service model where customers take their own blood sample using a fingerstick device at home
• Nightingale Pro

Products and services

• Nightingale Health Check The company's flagship advanced health check solution providing multi-disease risk detection from a single blood sample using proprietary NMR metabolomics technology; can be scaled to entire populations at low cost; targeted at healthcare providers, insurers, and government health systems.
• Remote Health Check An at-home health check solution enabling consumers to collect blood samples remotely using a fingerstick device and receive comprehensive multi-disease risk analysis through a mobile application; targeted at individual consumers and telehealth service providers.
• Nightingale Home Consumer-facing service model where individuals self-collect fingerstick blood samples using an easy-to-use device, mail the sample to Nightingale for NMR analysis, and receive results via a mobile application including a unique health index and health metrics.
• Nightingale Pro Full-service model for healthcare professionals with venous blood draw in a laboratory setting; provides a unique health index, health metrics, and detailed individual blood values to enable healthcare providers to support patients in lifestyle and treatment decisions.
• Terveystalo + Nightingale Well-being Membership Subscription-based well-being membership combining Nightingale's blood analysis with Terveystalo's well-being programs, including digital lifestyle coaching, regular measurements, health index, and indicators such as heart age, fatty acid balance, inflammation, and cholesterol balance.
• Venous Blood Analysis Research service analyzing venous blood samples to provide comprehensive NMR-based metabolomic biomarker data for academic, biobank, and medical research applications.
• Dried Blood Analysis + Nightingale Kit Research service analyzing dried blood spot samples using the proprietary Nightingale Kit, enabling convenient sample collection and shipment for metabolomic analysis in research settings.
• Urine Analysis Research service providing NMR-based metabolomic analysis of urine samples for health research applications.
• Metabolomics NMR-based metabolomics service providing comprehensive metabolic biomarker profiling from blood samples for research applications; recognized as a gold standard 'omics service for the research community.
• Proteomics Proteomics analysis service for research applications, extending Nightingale's multi-omics capabilities beyond metabolomics.
• Nightingale Analysis Service for Medical Research Comprehensive analysis service for medical researchers utilizing Nightingale's proprietary blood analysis technology and biomarker data platform for research applications.

Quantifiable outcome

• 44% improvement in prevention of heart attacks and strokes compared to current clinical practice
• +3 more outcomes

Named customers7 records

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered major, core and minor.

• Formula 100 HealthmajorStrategic or Co-development Partner · 22 May 2026Partnership in preventive health embedding multi-disease risk detection across longevity programs. Partnership brings Nightingale's disease risk assessment to Formula 100's longevity programs in Switzerland and South Africa.
• UK BiobankcoreStrategic or Co-development Partner · 20 November 2025Nightingale enables access to world's largest metabolomics dataset through UK Biobank collaboration. Nearly 250 metabolites measured in blood samples from 500,000 volunteers over several years. Combined with genetic, lifestyle, and medical information to enable predictive medicine at scale. Metabolite-based blood test for Type 2 diabetes risk prediction currently used in clinics in Finland and Singapore.
• 23andMemajorStrategic or Co-development Partner · 28 June 2024Strategic collaboration to pilot blood biomarker panel with cohort of 23andMe members. Pilot will evaluate utility of blood testing data in improving health risk assessments and lifestyle interventions. Offering up to 5,000 members free blood testing. Initiative toward making blood testing more accessible and integrated with genetic health services.
• Yliopiston ApteekkicoreChannel Partner/ Reseller/ Distributor · 27 October 2021Commercial partnership for nationwide distribution of Nightingale's at-home testing solution in Finland. At-home testing solution available through Yliopiston Apteekki's online pharmacy by end of 2021 and physical pharmacies nationwide during first half of 2022. Major milestone in commercialization of at-home testing offering.
• ReaktorminorImplementation/ SI/ Consulting Partner · 4 May 2021Strategic partnership with Reaktor for accelerating international growth. Reaktor provides consulting and implementation support for Nightingale's global expansion strategy.
• TerveystalocoreStrategic or Co-development Partner · 22 April 2021Strategic partnership agreement with Finland's largest healthcare company. Terveystalo develops new wellbeing services using Nightingale's blood analysis technology. New subscription service built and offered through Terveystalo application. Terveystalo receives exclusivity as private healthcare partner in Finland. Partnership valid at least until end of 2025 with expansion possibility to Nordic and Baltic countries. Revenue sharing model for service sales.
• BioBank JapancoreStrategic or Co-development Partner · 28 November 2020Long-term collaboration with one of the world's largest disease biobanks (over 200,000 participants, 640,000+ serum samples, 270,000 DNA samples). Joint research effort to identify disease risk factors in Japanese population for personalized medicine and prevention. Pilot phase started November 2020; ongoing sample analysis in Nightingale's Japan laboratory with over 10,000 samples analyzed. First results validated Nightingale's disease risk detection models for Japanese population.
• KIHUminorStrategic or Co-development Partner · 18 September 2019Partnership with KIHU (Jyväskylä University and Olympic Research) for athlete health and performance improvement. Nightingale's blood analysis technology used to support Finnish athletes.
• THL BiopankkicoreStrategic or Co-development Partner · 12 March 2018Collaboration to analyze 40,000 blood samples from Finland's largest biobank. Project aims to accelerate implementation of personalized healthcare in Finnish healthcare. Nightingale's technology enables analysis of large biobank samples at unprecedented scale and low cost.

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

Broad incumbents

• Guardant Health:
• Bruker Corporation: Bruker is a major manufacturer of NMR and mass spectrometry instruments, including metabolomics-capable platforms. It represents a potential supply and competitive threat: a large incumbent that could vertically integrate or partner with similar end-markets.
• Thermo Fisher Scientific: Thermo Fisher offers mass spectrometry-based metabolomics workflows, clinical diagnostic instruments, and laboratory services. It is a broad incumbent in analytical instruments and clinical diagnostics that competes for hospital, biobank, and research lab spend overlapping with Nightingale.
• Exact Sciences: Exact Sciences is a multi-biomarker diagnostics company (Cologuard, Oncotype) selling blood- and stool-based screening tests into clinical workflows. It is a broader incumbent in blood-based multi-disease screening and a comparable reference point for scaling a biomarker-based clinical platform.
• Quest Diagnostics: Quest Diagnostics is a large US clinical laboratory network offering routine and specialty blood testing. It is a broader incumbent in medical laboratory services and a likely partner or competitor for population-scale screening deployments.

Direct peers

• Metabolon: Metabolon is the most direct competitor in metabolomics profiling, offering mass spectrometry-based biomarker analysis to research and clinical customers. Both companies compete for biobank and pharmaceutical research contracts and overlap heavily in disease risk biomarker discovery.

Emerging players

• GRAIL: GRAIL develops blood-based multi-cancer early detection tests (Galleri). It overlaps with Nightingale in using a single blood draw to detect risk for multiple diseases, and represents a high-profile emerging player in multi-disease blood screening.
• Freenome: Freenome is developing blood-based tests for early cancer detection using multi-omics approaches. It is an emerging player with a partial overlap with Nightingale in single-blood-draw, multi-disease risk detection.
• InsideTracker: InsideTracker offers consumer-facing blood-based health and wellness testing with personalized recommendations. It is an emerging player in the consumer blood testing segment where Nightingale's Remote Health Check and Terveystalo membership compete.
• Function Health: Function Health sells consumer subscription blood testing (300+ biomarkers) with a focus on prevention and longevity. It is an emerging player in the same consumer preventive health subscription category as Nightingale's Terveystalo membership and Remote Health Check.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/nightingale-health
• Xx.com/ngalehealth

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nightingale Health